Try our Advanced Search for more refined results

Expert Analysis

Interpreting Stock Reactions To Reverse-Payment Settlements

Law360, New York (February 11, 2015, 4:30 PM EST) -- When branded drug companies settle patent litigation (known as Paragraph IV or Hatch-Waxman litigation) with would-be generic competitors, they sometimes enter into contemporaneous business agreements with the generic companies. There is a concern that such agreements may constitute payments from the brand company to the generic company (so-called "reverse payments") in exchange for the generic company agreeing to delay entry beyond the date that would be expected were the patent case litigated....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!